Allergic rhinitis (AR) is a common condition, affecting around 18% of people (children and adults) in Australia and New Zealand. AR has significant impact on quality-of-life, emotional wellbeing and productivity, especially for people with co-existing asthma.
This GP education program is based on the Australasian Society of Clinical Immunology and Allergy (ASCIA) best practice and will review the differences between allergic and other types of rhinitis, and cover pharmacological and non-pharmacological approaches to the management of moderate-to-severe allergic rhinitis.
Using a person-centred approach to the management of AR, the program will detail the current AR treatment algorithm, including when to consider intra-nasal combination pharmacotherapy.
This program is supported by an independent, educational grant provided from Viatris.